Iovance Biotherapeutics, Inc.IOVANASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,710 shares of Iovance's common stock to 17 new, non-executive employees.

globenewswire.com

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) If you have held Iovance Biotherapeutics, Inc. shares continuously since prior to May 9, 2024, you may have standing to seek corporate governance reforms at Iovance, including improvements to internal controls, transparency, and executive oversight.

fool.com

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges.

seekingalpha.com

Iovance Biotherapeutics: Bright Prospects For 2026

Iovance Biotherapeutics is reaffirmed as a Buy, driven by Amtagvi's strong efficacy and blockbuster potential in melanoma and lung cancer. IOVA targets significant market expansion, with lung cancer representing a $10B U.S. peak sales opportunity—7x its current melanoma market. Operational risks persist: slow commercial ramp, steep operating losses, and competition from Replimune's RP1, but management expects gross margin gains from in-house manufacturing in 2026.

defenseworld.net

Comparing Iovance Biotherapeutics (NASDAQ:IOVA) & Black Diamond Therapeutics (NASDAQ:BDTX)

Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Volatility and Risk Black Diamond Therapeutics

globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 18, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 43,150 shares of Iovance's common stock to four new, non-executive employees.

fool.com

2 Stocks That Could Soar by 52% and 282%, According to Wall Street

CRISPR Therapeutics' approved medicine is making slow progress, but it has an exciting pipeline. Iovance Biotherapeutics is generating decent revenue, but it faces significant obstacles.

globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on November 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 164,900 shares of Iovance's common stock to 11 new, non-executive employees.

defenseworld.net

AE Wealth Management LLC Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

AE Wealth Management LLC bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 52,947 shares of the biotechnology company's stock, valued at approximately $91,000. Several other hedge funds have also made

seekingalpha.com

Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode

Iovance Biotherapeutics remains a Sell due to ongoing dilution risk, sub-consensus revenue, and only modest margin improvements. Q3 revenue landed in the base case at $68 million, missing estimates, while gross margin improved to 29.6% (≤30% adjusted for D&A). Management reaffirmed FY25 revenue guidance and extended cash runway to Q2 2027, but execution and credibility issues persist.

fool.com

Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?

Iovance obtained approval for Amtagvi last year, which has given its top line a big boost. This year, the company anticipates it can generate up to $300 million in sales.

zacks.com

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.

fool.com

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street

Iovance Biotherapeutics and Intellia Therapeutics are two innovative small-cap biotechs. Both companies face serious issues despite Wall Street's high price targets for them.

seekingalpha.com

Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript

Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Sara Pellegrino - Senior Vice President of Investor Relations & Corporate Communications Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen Roche - Chief Financial Officer Daniel Kirby - Chief Commercial Officer Igor Bilinsky - Chief Operating Officer Friedrich Graf Finckenstein - Chief Medical Officer Raj Puri - Chief Regulatory Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Salim Syed Nicholas Lorusso - TD Cowen, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Presentation Operator Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2025 Conference Call.

zacks.com

Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.

globenewswire.com

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 62,790 shares of Iovance's common stock to nine new, non-executive employees.

fool.com

Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health

Here's a great way to earn strong market returns over the long term: Identify companies that have been ignored or underestimated by most investors but have attractive prospects; buy their shares at a deep discount; and hold on to them for a long time. Picking out such corporations isn't easy, though.

fool.com

Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?

Most investors don't truly expect a single, relatively small trade to explode into a seven-figure holding. On the other hand, the prospect can't be entirely ruled out either.

seekingalpha.com

Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play

Iovance Biotherapeutics (IOVA) maintains a Buy rating, supported by growing Amtagvi sales, promising efficacy data, and ongoing label expansion opportunities. IOVA's restructuring aims to cut over $100 million in annual costs, extending its cash runway and supporting continued pipeline development despite ongoing heavy losses. The rejection of a key competitor's therapy by the FDA boosts IOVA's market prospects, but profitability remains uncertain due to high costs and slow revenue ramp.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance